ipopba/iStock via Getty Images
Flexion Therapeutics (NASDAQ:FLXN) continues to report steady revenue growth as ZILRETTA moves deeper into commercialization. Despite the ongoing pandemic, Flexion reported encouraging Q1 earnings that revealed commercial…

Click here to view the original article.